/ /

  • linkedin
  • Increase Font
  • Sharebar

    Study explores ranibizumab as treatment for ROP


    Study design and patient characteristics

    The study analyzed data from two consecutive cohorts of patients. It included 37 eyes of 21 patients treated with bevacizumab (0.25 mg/eye) from January 2012 to June 2015 and 27 eyes of 14 patients treated with ranibizumab (0.25 mg/eye) between July 2015 and July 2016.

    The indications for anti-VEGF therapy varied. In 35 eyes, anti-VEGF was injected as salvage therapy, 17 eyes received anti-VEGF injection as an adjunct to vitrectomy, and only 12 eyes in the study received the anti-VEGF injection as monotherapy.

    “In Japan, we still consider laser as first-line treatment,” Dr. Kusaka explained.

    All of the infants were outborn. The two groups were similar in their baseline characteristics. Overall follow-up ranged from 3 to 65 months, but the mean follow-up was significantly longer for the bevacizumab group than for the ranibizumab-treated eyes (11 versus 39 months).

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results